{
    "nctId": "NCT00381368",
    "briefTitle": "Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients",
    "officialTitle": "Phase II Open Label Study to Establish the Safety and Efficacy of Intravenous Loading Dose of Ibandronate 6 mg in 3 Consecutive Days in Breast Cancer Patients With Skeletal Metastases",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Worst and average pain in movement and rest on the visual analogue scale (VAS) before the first dose, on days 2, 3, 7 and on day 28",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer with presence of bone metastases\n* Pain score over 4 on the VAS\n\nExclusion Criteria:\n\n* Patients with pathological fractures or medulla compression or neuropathic pain\n* Patients with infection or corticosteroid treatment\n* Pregnant or lactating patients",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}